

What is claimed:

amb  
B3

1. An isolated polypeptide having a portion of SEQ ID NO:1 having VEGF antagonist activity.

2. An isolated polypeptide comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity.

3. An isolated polypeptide comprising a peptide having the structure of the following formula (I):



wherein  $X_1$  is H, or any portion of amino acids 2-21 of SEQ ID NO: 1, and  $X_2$  is H or C, CR, RC or CRC, and analogs thereof.

amb  
B4

4. A pharmaceutical composition comprising a polypeptide of claims 1, 2 or 3 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, wherein the carrier is acceptable for topical application to the skin.

6. The pharmaceutical composition of claim 4, wherein the carrier is acceptable for application to the eye.

7. A method of treating a subject having disease or disorder associated with VEGF, which comprises administering to the subject a pharmaceutical composition of claim 4.

9. The method of claim 7, wherein said disease or disorder associated with VEGF is selected from the group consisting of Kaposi's sarcoma, osteoarthritis, diabetic retinopathy, and rheumatoid arthritis.

11. A method for treating a tumor expressing a VEGF<sub>165</sub>R/NP-1 receptor comprising administering to said host a pharmaceutical composition of claim 4.

13. Use of the isolated nucleic acid of claim 12 in the preparation of a medicament for treating a disease or disorder associated with VEGF.

14. Use of the polypeptide of claims 1-3 in the preparation of a medicament for treating a disease or disorder associated with VEGF.